Targets › UCN2
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2028.
Hormone that plays a central role in whole body adaptation to stress. Released by the hypothalamus primarily in response to physical or psychological stress and acts by binding to CRH receptor CRHR2. (UniProt, Q96RP3)
Open in Phaseline: the race on UCN2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gubra | GUB-UCN2 Urocortin 2 analog | UCN2 | Phase 1 | Obesity | Dec 2028 |
Obesity (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.